Tepotinib latest price reference information in 2025

Tepotinib is an oral targeted drug targeting the MET gene exon 14 skipping mutation (METex14). It is mainly used to treat advanced non-small cell lung cancer with related mutations. With the continuous emphasis on precision medicine, this drug has been officially approved for marketing in my country in recent years and has been included in the medical insurance catalog. This is a positive signal for the majority of patients, especially those with greater financial pressure. However, although the burden can be reduced to a certain extent after being included in medical insurance, the domestic retail price of the original drug is still relatively high, with the cost of each box being approximately more than 30,000 yuan.

For patients who use domestic medical insurance to reimburse tepotinib, the specific reimbursement ratio, deductible and actual payment amount may vary due to different regional policies. It is recommended that patients consult the hospital or local medical insurance department before taking the medicine to understand whether the specific specifications are covered by the medical insurance catalog and the outpatient or inpatient reimbursement process. Some regions may also provide special drug outpatient reimbursement or chronic disease registration policies to help patients who take long-term medications reduce their burden.

In addition to the domestic original drug market, some patients currently also choose overseas channels to purchase more affordable generic drugs. Among them, the generic version on the Lao market has attracted the most attention, especially the generic version of tepotinib produced by Laos Lucius Pharmaceutical Factory and Lao Daxiong Pharmaceutical Factory. The price has been significantly reduced recently. According to market data, the price of this type of generic version has dropped to more than 6,000 yuan per box. The drug ingredients are basically the same as the original drug, and the effect has been good in actual clinical use. It is a more feasible option for patients who do not have medical insurance or cannot afford the high price of the original drug.

Taken together, as a targeted therapy drug with clear clinical value, the domestic price of tepotinib is relatively high, but because it has been included in medical insurance, the economic burden has been eased; and the price advantage of overseas generic drugs also provides patients with more treatment options. No matter which way to purchase medicines, patients should use medicines rationally under the guidance of doctors and ensure that the sources of medicines are formal and legal to avoid improper purchase channels that may affect the treatment effect or bring additional risks.

Reference materials:https://www.tepotinib.com/